Fractional dose of scarce meningitis vaccine may be effective in outbreak controlDecember 05, 2008One fifth of the standard dose of a commonly used meningitis vaccine may be as effective as using the full dose. This new finding should allow scarce vaccine resources to be stretched further, especially during epidemics in Africa. In a study initiated by the Norwegian Institute of Public Health, together with Epicentre (the research arm of Doctors Without Borders/Médecins Sans Frontières), and Mbarara University of Science and Technology in Uganda, immune responses in patients receiving smaller doses of a meningitis vaccine were found to be comparable to a full dose. In 2004, a randomized clinical trial of 750 healthy volunteers (2-19 years old) took place in Uganda. Their immune response, assessed by serum bactericidal activity (SBA), was measured for 1/5 and 1/10 doses compared to a full dose. SBA response and safety/tolerability using 1/5 dose were comparable to a full dose for three serogroups (A, Y, W135), but not a fourth (C). In view of the current shortage of meningococcal vaccines for Africa, the use of 1/5 fractional doses should be considered as an alternative in mass vaccination campaigns. The study's findings contributed to a 2007 WHO recommendation that a fractional dosing strategy be utilized in the event of severe vaccine shortages during a meningitis epidemic. The results have now been published in PLoS Neglected Tropical Diseases. Norwegian Institute of Public Health |
|||||||||||||||||||||
| Related Meningitis Vaccine Current Events and Meningitis Vaccine News Articles Improved meningitis vaccine for Africa could signal eventual end to to deadly scourge The Meningitis Vaccine Project (MVP) today released new data on the performance of a meningitis vaccine in West African children, suggesting that the new vaccine-expected to sell initially for 40 US cents a dose-will be much more effective in protecting African children and their communities than any vaccine currently on the market in the region. Hope For New Meningitis Vaccine Research performed by scientists at the School of Biomedical and Molecular Sciences, University of Surrey and the Health Protection Agency (Porton Down, Salisbury) provides hope for developing a new meningitis vaccine that will protect children against all groups of meningococcus. Published in the journal, Infection and Immunity, the research found that meningococcus is responsible for epidemics of meningitis worldwide that kills thousands of children each year. Vaccines are available for the A and C groups, but no effective vaccine is currently available for B groups. There are about 1500 confirmed cases of group B meningitis in the UK each year, but the true incidence is likely to be neare More Meningitis Vaccine Current Events and Meningitis Vaccine News Articles |
|||||||||||||||||||||
|
|||||||||||||||||||||
|
|||||||||||||||||||||